A new preclinical imaging agent, designed to aid the development of personalised therapies for breast cancer has been developed. The device is called HER2Sense and it has been created by the company PerkinElmer.
HER2Sense is a fluorescent research imaging agent, based on a commercialised therapeutic antibody. It is able to specifically detect a specific receptor for the treatment of various forms of cancer.
The imaging agent has the potential to provide oncology researchers with new data and insights that could influence the development of methods for detecting a range of cancers.
For more details, see the report on BioSpace.